MiMedx Investor Trigran Reports 5.1% Stake Without An Aim To Influence Control

The investment adviser reported 7,391,329 shares, with shared voting power covering 6,753,733 shares.

Share
MiMedx Investor Trigran Reports 5.1% Stake Without An Aim To Influence Control

Trigran Investments, an investment adviser, reported Thursday a 5.1% stake in MiMedx Group, which makes tissue-based treatments for hard-to-heal wounds. Its SEC passive ownership disclosure put the holding at 7,391,329 common shares as of September 30, 2026, and certified that the investment carries no aim to change or influence company control.

Shared Votes, A Passive Holding

Trigran reported shared voting power over 6,753,733 shares and zero shares over which it alone controls the vote. The 5.1% figure measures its reported ownership of MiMedx's common-stock class.

The adviser certified that it bought and holds the securities as part of its regular business. Its certification also covers participation in transactions intended to change or influence MiMedx's control.

The ownership report includes Douglas T. Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon and Steven R. Monieson, Trigran's controlling shareholders and officers. Because they control the adviser, they may be treated as beneficial owners of the shares it reports. The same holding appears under their names; those entries describe overlapping ownership.

Placental Tissue Drives MiMedx's Business

MiMedx's core products are allografts—treatments made using donated human tissue. It processes placental membrane, umbilical cord and placental disc tissue at facilities in Georgia for use in wound care, surgery and burn treatment.

The company also sells a collagen product derived from cattle and distributes other manufacturers' wound-care products through exclusive agreements. Buyers range from doctors' practices and wound-treatment centers to hospitals, nursing homes and federal facilities, including Department of Veterans Affairs facilities.

MiMedx reaches customers through its own salespeople, independent agents and distributors. Gunze Medical is a distributor in Japan, though domestic sales generate the vast majority of revenue.

In its annual report for the fiscal year ended December 31, 2025, MiMedx reported payer coverage spanning more than 300 million covered lives and 82 U.S. patents tied to its amniotic-tissue technology.

MiMedx had a market value of $484 million in Thursday's original report, as of 4:38 p.m. ET.

Sources

More on MiMedx Group

All MiMedx Group (MDXG) coverage →